Denise E Sabatino

List of Publications by Year
in descending order

36 papers	2,907 citations	687363 13 h-index	552781 26 g-index
36 all docs	36 docs citations	36 times ranked	2533 citing authors

#	Article	IF	Citations
1	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	30.7	1,865
2	A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nature Biotechnology, 2021, 39, 47-55.	17.5	238
3	Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors. Molecular Therapy, 2011, 19, 442-449.	8.2	116
4	Persistent Expression of hF.IX After Tolerance Induction by In Utero or Neonatal Administration of AAV-1-F.IX in Hemophilia B Mice. Molecular Therapy, 2007, 15, 1677-1685.	8.2	96
5	Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Science Advances, 2020, 6, .	10.3	88
6	Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Molecular Therapy, 2005, 12, 1023-1033.	8.2	85
7	Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood, 2013, 121, 4396-4403.	1.4	70
8	Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. Molecular Therapy, 2022, 30, 2646-2663.	8.2	65
9	Animal Models of Hemophilia. Progress in Molecular Biology and Translational Science, 2012, 105, 151-209.	1.7	62
10	Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16064.	4.1	59
11	Recombinant canine B-domainâ€“deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood, 2009, 114, 4562-4565.	1.4	55
12	Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Blood, 2004, 104, 2767-2774.	1.4	32
13	Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.. Blood, 2004, 104, 413-413.	1.4	13
14	Infused factor VIIIâ€“expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A. Blood Advances, 2019, 3, 1368-1378.	5.2	12
15	Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 610-615.	2.1	8
16	Challenges in estimating numbers of vectors integrated in gene-modified cells using DNA sequence information. Molecular Therapy, 2021, 29, 3328-3331.	8.2	7
17	Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A. Molecular Therapy - Methods and Clinical Development, 2022, 24, 20-29.	4.1	7
18	Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 575-580.	2.1	6

#	Article	IF	Citations
19	Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII. Blood, 2008, 112, 243-243.	1.4	4
20	Understanding Ectopically Expressed Factor VIII (F8) In Megakaryocytes: Implications for Optimum Platelet-Delivered F8 Activity for Gene Therapy. Blood, 2010, 116, 2205-2205.	1.4	4
21	Topics in AAV integration come front and center at ASGCT AAV Integration Roundtable. Molecular Therapy, 2021, 29, 3319-3320.	8.2	4
22	Overexpression of Factor VIII Is Associated with Immune Responses to Factor VIII and Cellular Stress in Hemophilia A Mice. Blood, 2011, 118, 22-22.	1.4	3
23	Clogging up the pipeline: factor VIII aggregates. Blood, 2020, 135, 1825-1827.	1.4	2
24	AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid.. Blood, 2006, 108, 455-455.	1.4	2
25	A Novel Approach for Generating Platelet-Delivered FVIII: Role of Transient LRP1 Expression during Megakaryopoiesis. Blood, 2019, 134, 1102-1102.	1.4	2
26	Identification of the AAV2 Capsid CD8+ T Cell Epitope in C57BL/6 Mice.. Blood, 2004, 104, 3188-3188.	1.4	1
27	Muscle Gene Therapy for Hemophilia. Journal of Genetic Syndromes & Gene Therapy, 2013, S1, .	0.2	1
28	T Cell Responses to AAV Vector Capsid Limit the Duration of Transgene Expression in Humans after Liver-Directed Gene Therapy.. Blood, 2005, 106, 3055-3055.	1.4	0
29	Characterization of the Immune Response to Canine Factor IX Following AAV-Mediated Intravascular Gene Delivery to Skeletal Muscle in Hemophilia B Dogs.. Blood, 2005, 106, 1297-1297.	1.4	0
30	Long Term Dose-Dependent Correction of Hemophilia A Dogs Using AAV-8 and AAV-9-Mediated FVIII Gene Transfer.. Blood, 2006, 108, 999-999.	1.4	0
31	Successful Long Term Therapeutic Expression of Factor VIII in Hemophilia A Dogs After Administration of AAV-cFVIII Using a Two-Chain or Single Chain Delivery Approach.. Blood, 2009, 114, 546-546.	1.4	0
32	Reconstitution of Recombinant Factor VIII In fVIII-/- mice Restores Von Willebrand Factor Homeostasis. Blood, 2010, 116, 2213-2213.	1.4	0
33	Bioengineering Factor VIII B-Domain Sequences Improves Function and Efficacy in Hemophilia A Models.. Blood, 2012, 120, 2208-2208.	1.4	0
34	Platelet Factor VIII-Induced Megakaryocyte Apoptosis: Implications for Hemophilia A Gene Therapy. Blood, 2012, 120, 2051-2051.	1.4	0
35	Novel Human Factor VIII Variant with Impaired Intracellular Processing Exhibits Enhanced In Vivo Efficacy. Blood, 2016, 128, 256-256.	1.4	0
36	Generation of a Unique Cohort of Hemophilia A Dogs Tolerant to Human FVIII for Evaluating the Safety and Efficacy of AAV Delivery of Wild Type and Variant Human FVIII. Blood, 2018, 132, 2453-2453.	1.4	0